UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934
Release No. 88627 / April 13, 2020

The Securities and Exchange Commission (“Commission”) announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the “Exchange Act”), of trading in the securities Applied BioSciences Corp. (“APPB”) (CIK #001607549) of Beverly Hills, California at 9:30 a.m. EDT on April 14, 2020, and terminating at 11:59 p.m. EDT on April 27, 2020.

The Commission temporarily suspended trading in the securities of APPB because questions have arisen concerning the accuracy and adequacy of publicly-available information concerning APPB. The questions relate to statements that APPB made about selling coronavirus test kits for home use in a March 31, 2020 press release issued by the Company.

The Commission cautions broker-dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company.

Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has any questions as to whether or not he has complied with the rule, he should not enter any quotation but immediately contact the staff in the Division of Trading and Markets, Office of Interpretation and Guidance, at (202) 551-5777. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, he should refrain from entering quotations relating to APPB’s securities until such time as he has familiarized himself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action.

If any broker-dealer or other person has any information which may relate to this matter, contact Thomas P. Smith, Jr., Assistant Regional Director, New York Regional Office, at (212) 336-0171, or Kristine Zaleskas, Senior Counsel, New York Regional Office, at (212) 336-0189. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.